Glenmark Reaps Favipiravir Gains, Progresses COVID-19 Nasal Spray
Emergency India Go-Ahead For NO Spray?
Strong run on Indian market for Glenmark in fiscal Q1, with the company optimistic of prospects for new introductions including generic Brovana in the US, where it expects close to double-digit growth in Q2. All eyes are also on the launch timelines of a partnered nitric oxide nasal spray for COVID-19.
You may also be interested in...
Cipla signals more US momentum with headroom for albuterol market share expansion, promising prospects for generic Brovana and strong launch line-up in FY23, but analysts also keep close eye on regulatory pre-approval inspection timelines.
Glenmark expects its first US manufacturing site to go commercial next year, accelerating growth in that market, while it sets right certain compliance blips back home. The Indian firm is also on course to divest certain non-core assets but notes that bringing in a minority partner for its API unit is not a priority.
Amgen’s former chief information officer Diana McKenzie highlights the inroads made by technology firms in healthcare and how life science companies can adapt from them while leveraging core capabilities at scale.